This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014; 65:1095-106.ZnaorALortet-TieulentJJemalABrayF.International variations and trends in testicular cancer incidence and mortalityEur Urol201465109510610.1016/j.eururo.2013.11.00424268506Search in Google Scholar
Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology 2015; 3: 4-12.TrabertBChenJDevesaSSBrayFMcGlynnKAInternational patterns and trends in testicular cancer incidence overall and by histologic subtype 1973-2007Andrology2015341210.1111/andr.293441083925331326Search in Google Scholar
Kovač V. The cause of testicular cancer. Radiol Oncol 1998; 32: 201-5.KovačV.The cause of testicular cancerRadiol Oncol1998322015Search in Google Scholar
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. [citated 2 Feb 2016]. Available at https://seer.cancer.gov/ statfacts/htlm/testis.htlmNational Cancer InstituteSurveillance, Epidemiology, and End Results (SEER) Program. [citated 2 Feb 2016]Available athttps://seer.cancer.gov/ statfacts/htlm/testis.htlmSearch in Google Scholar
Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al.. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99: 533-44.FossaSDGilbertEDoresGMChenJMcGlynnKASchonfeldSet alNoncancer causes of death in survivors of testicular cancerJ Natl Cancer Inst2007995334410.1093/jnci/djk11117405998Search in Google Scholar
De Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European EORTC-GTCCG and. J Clin Oncol 2001; 19: 1629-40.De WitRRobertsJTWilkinsonPMde MulderPHMMeadGMFossaSDet al.Equivalence of three or four cycles of bleomycin etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European EORTC-GTCCG andJ Clin Oncol20011916294010.1200/JCO.2001.19.6.162911250991Search in Google Scholar
Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol 1998; 16: 702-6.SaxmanSBFinchDGoninREinhornLHLong-term follow up of a phase III study of three versus four cycles of bleomycin etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experienceJ Clin Oncol199816702610.1200/JCO.1998.16.2.7029469360Search in Google Scholar
Nichols CR, Wiliams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 1991; 9: 1163-72.NicholsCRWiliamsSDLoehrerPJGrecoFACrawfordEDWeetlauferJet alRandomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group ProtocolJ Clin Oncol1991911637210.1200/JCO.1991.9.7.11631710655Search in Google Scholar
Fossa SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A MRC randomized trial. J Clin Oncol 1999; 17: 1146.FossaSDHorwichARussellJMRobertsJTCullenMHHodsonNJet alOptimal planning target volume for stage I testicular seminoma: A MRC randomized trialJ Clin Oncol199917114610.1200/JCO.1999.17.4.114610561173Search in Google Scholar
Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I seminoma: A report on MRC Trial TE 18, EORTC Trial 30942. J Clin Oncol 2005; 23: 1200-8.JonesWGFossaSDMeadGMRobertsJTSokalMHorwichAet alRandomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I seminoma: A report on MRC Trial TE 18, EORTC Trial 30942J Clin Oncol2005231200810.1200/JCO.2005.08.00315718317Search in Google Scholar
Kovač V. Prevention of fertility disturbances in oncological male patients. Radiol Oncol 1996; 30: 286-90.KovačV.Prevention of fertility disturbances in oncological male patientsRadiol Oncol19963028690Search in Google Scholar
Horwich A, Alsanjari N, A´Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma.Br J Cancer 1992; 65: 775-8.HorwichAAlsanjariNA´HernRNichollsJDearnaleyDPFisherC.Surveillance following orchidectomy for stage I testicular seminomaBr J Cancer199265775810.1038/bjc.1992.16419773981586607Search in Google Scholar
Van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-75.Van den Belt-DuseboutAWNuverJde WitRGietemaJAtenBokkelHuininkWWRodrigusPTet alLong-term risk of cardiovascular disease in 5-year survivors of testicular cancerJ Clin Oncol2006244677510.1200/JCO.2005.02.719316421423Search in Google Scholar
Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 2010; 28: 4649-57.HaugnesHSWethalTAassNDahlOKleppOLangbergCWet alCardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up studyJ Clin Oncol20102846495710.1200/JCO.2010.29.9362Search in Google Scholar
Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer.J Clin Oncol 1992; 10: 1386-9.RaghavanDCoxKChildsAGrygielJSullivanD.Hypercholesterolemia after chemotherapy for testis cancerJ Clin Oncol1992101386910.1200/JCO.1992.10.9.1386Search in Google Scholar
Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 4980-90.SagstuenHAassNFossaSDDahlOKleppOWistEAet alBlood pressure and body mass index in long-term survivors of testicular cancerJ Clin Oncol20052349809010.1200/JCO.2005.06.882Search in Google Scholar
Nord C, Fossa SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer.Br J Cancer 2003; 88:36-41.NordCFossaSDEgelandT.Excessive annual BMI increase after chemotherapy among young survivors of testicular cancerBr J Cancer200388364110.1038/sj.bjc.6600714Search in Google Scholar
Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-36.StrumbergDBruggeSKornMWKoeppenSRanftJScheiberGet alEvaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancerAnn Oncol2002132293610.1093/annonc/mdf058Search in Google Scholar
Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-32.MeinardiMTGietemaJAvan der GraafWTAvan VeldhuisenDJRunneMASluiterWJet alCardiovascular morbidity in long-term survivors of metastatic testicular cancerJ Clin Oncol20001817253210.1200/JCO.2000.18.8.1725Search in Google Scholar
Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989; 7: 1099-104.StoterGKoopmanAVendrikCPStruyvenbergASleyferDTWillemsePHet alTen-year survival and late sequelae in testicular cancer patients treated with cisplatin vinblastine, and bleomycinJ Clin Oncol19897109910410.1200/JCO.1989.7.8.1099Search in Google Scholar
Gietema JA, Sleijfer DT, Willemse PH, Schraffordt HK, van Ittersum E, Verschuren WM, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116: 709-15.GietemaJASleijferDTWillemsePHSchraffordtHKvan IttersumEVerschurenWMet alLong-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancerAnn Intern Med19921167091510.7326/0003-4819-116-9-709Search in Google Scholar
Hanks GE, Peters T, Owen J. Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992; 24:913-19.HanksGEPetersTOwenJ.Seminoma of the testis: long-term beneficial and deleterious results of radiationInt J Radiat Oncol Biol Phys1992249131910.1016/0360-3016(92)90475-WSearch in Google Scholar
Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640-7.ZagarsGKBalloMTLeeAKStromSSMortality after cure of testicular seminomaJ Clin Oncol200422640710.1200/JCO.2004.05.20514726503Search in Google Scholar
Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004; 90: 607-12.FossaSDAassNHarveiSTretliS.Increased mortality rates in young and middle-aged patients with malignant germ cell tumoursBr J Cancer2004906071210.1038/sj.bjc.6601558Search in Google Scholar
Van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwmann MWJ, Ribot JG, et al. Treatment-specific risk of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25: 4370-8.Van den Belt-DuseboutAWde WitRGietemaJAHorenblasSLouwmannMWJRibotJGet alTreatment-specific risk of second malignancies and cardiovascular disease in 5-year survivors of testicular cancerJ Clin Oncol2007254370810.1200/JCO.2006.10.5296Search in Google Scholar
Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-23.HuddartRANormanAShahidiMHorwichACowardDNichollsJet alCardiovascular disease as a long-term complication of treatment for testicular cancerJ Clin Oncol20032115132310.1007/978-1-4471-3281-3_45Search in Google Scholar
Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19: 253-6.SamuelsBLVogelzangNJKennedyBJSevere vascular toxicity associated with vinblastine bleomycin, and cisplatin chemotherapyCancer Chemother Pharmacol198719253610.1007/BF00252982Search in Google Scholar
Lederman GS, Sheldon TA, Chaffey JT, Herman TS, Gelman RS, Coleman CN. Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987; 60: 772-6.LedermanGSSheldonTAChaffeyJTHermanTSGelmanRSColemanCN.Cardiac disease after mediastinal irradiation for seminomaCancer198760772610.1002/1097-0142(19870815)60:4<772::AID-CNCR2820600411>3.0.CO;2-ASearch in Google Scholar
Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14:2923-32.BokemeyerCBergerCCKuczykMASchmollHJEvaluation of long-term toxicity after chemotherapy for testicular cancerJ Clin Oncol19961429233210.1200/JCO.1996.14.11.2923Search in Google Scholar
Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell´Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18.PedrinelliRGiampietroOCarmassiFMelilloEDell´OmoGCatapanoGet alMicroalbuminuria and endothelial dysfunction in essential hypertensionLancet1994344141810.1016/S0140-6736(94)91047-2Search in Google Scholar
Stehouwer CD, Yudkin JS, Fioretto P, Nosadini R. How heterogeneous is microalbuminuria in diabetes mellitus? The case for „benign“ and „malignant“ microalbuminuria. Nephrol Dial Transplant 1998; 13: 2751-4.StehouwerCDYudkinJSFiorettoPNosadiniRHow heterogeneous is microalbuminuria in diabetes mellitus? The case for „benign“ and „malignant“ microalbuminuriaNephrol Dial Transplant1998132751410.1093/ndt/13.11.2751Search in Google Scholar
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.HillegeHLFidlerVDiercksGFvan GilstWHde ZeeuwDvan VeldhuisenDJet alUrinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general populationCirculation200210617778210.1161/01.CIR.0000031732.78052.81Search in Google Scholar
Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701-6.NuverJSmitAJSleijferDTvan GesselAIvan RoonAMvan der MeerJet alMicroalbuminuria, decreased fibrinolysis and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancerEur J Cancer200440701610.1016/j.ejca.2003.12.012Search in Google Scholar
Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.ThogersenAMJanssonJHBomanKNilssonTKWeinehallLHuhtasaariFet alHigh plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for fibrinolytic system as an independent primary risk factorCirculation1998982241710.1161/01.CIR.98.21.2241Search in Google Scholar
Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.Juhan-VagueIPykeSDAlessiMCJespersenJHaverkateFThompsonSGFibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and DisabilitiesCirculation19969420576310.1161/01.CIR.94.9.2057Search in Google Scholar
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.RidkerPMCushmanMStampferMJTracyRPHennekensCHInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy menN Engl J Med1997336973910.1056/NEJM199704033361401Search in Google Scholar
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.DaneshJWheelerJGHirschfieldGMEdaSEiriksdottirGRumleyAet alC-reactive protein and other circulating markers of inflammation in the prediction of coronary heart diseaseN Engl J Med200435013879710.1056/NEJMoa032804Search in Google Scholar
Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009; 31: 79-94.CalabroPGoliaEYehETCRP and the risk of atherosclerotic eventsSemin Immunopathol200931799410.1007/s00281-009-0149-4Search in Google Scholar
Sellmayer A, Limmert T, Hoffmann U. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or usefull screening? Int Angiol 2003; 22: 15-23.SellmayerALimmertTHoffmannU.High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or usefull screening?Int Angiol2003221523Search in Google Scholar
Nuver J, Smit AJ, van der Meer J, van den Berg MP, van den Graaf WTA, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-7.NuverJSmitAJvan der MeerJvan den BergMPvan den GraafWTAMeinardiMTet alAcute chemotherapy-induced cardiovascular changes in patients with testicular cancerJ Clin Oncol2005239130710.1200/JCO.2005.01.4092Search in Google Scholar
Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355: 1075-6.GietemaJAMeinardiMTMesserschmidtJGelevertTAltFUgesDRet alCirculating plasma platinum more than 10 years after cisplatin treatment for testicular cancerLancet20003551075610.1016/S0140-6736(00)02044-4Search in Google Scholar
Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 2006; 4: 1059-70.EfstathiouELogothetisCJReview of late complications of treatment and late relapse in testicular cancerJ Natl Compr Canc Netw2006410597010.6004/jnccn.2006.0088Search in Google Scholar
Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012; 30: 300-7.SprautenMDarrahTHPetersonDRCampbellMEHanniganRECvancarovaMet alImpact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancerJ Clin Oncol201230300710.1200/JCO.2011.37.4025Search in Google Scholar
Verheij M, Dewit LG, Valdes Olmos RA, Arisz L. Evidence for a renovascular component in hypertensive patients with late radiation nephropathy. Int J Radiat Oncol Biol Phys 1994; 30: 677-83.VerheijMDewitLGValdes OlmosRAAriszLEvidence for a renovascular component in hypertensive patients with late radiation nephropathyInt J Radiat Oncol Biol Phys1994306778310.1016/0360-3016(92)90955-HSearch in Google Scholar
Kim TH, Somerville PJ, Freeman CR. Unilateral radiation nephropathy – the long-term significance. Int J Radiat O ncol Biol Phys 1984; 10: 2053-9.KimTHSomervillePJFreemanCRUnilateral radiation nephropathy – the long-term significanceInt J Radiat O ncol Biol Phys1984102053910.1016/0360-3016(84)90202-5Search in Google Scholar
Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995; 31: 1249-56.CassadyJR.Clinical radiation nephropathyInt J Radiat Oncol Biol Phys19953112495610.1016/0360-3016(94)00428-NSearch in Google Scholar
Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-8.HaugnesHSAassNFossaSDDahlOKleppOWistEAet alComponents of the metabolic syndrome in long-term survivors of testicular cancerAnn Oncol200718241810.1093/annonc/mdl372Search in Google Scholar
Nuver J, Smit AJ, Wolffenbuttel BHR, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.J Clin Oncol 2005; 23: 3718-25.NuverJSmitAJWolffenbuttelBHRSluiterWJHoekstraHJSleijferDTet alThe metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancerJ Clin Oncol20052337182510.1200/JCO.2005.02.176Search in Google Scholar
Gietema JA, Meinardi MT, van der Graff WT, Sleijfer DT. Syndrome X in testicular cancer survivors. Lancet 2001; 357: 228-9.GietemaJAMeinardiMTvan der GraffWTSleijferDTSyndrome X in testicular cancer survivorsLancet2001357228910.1016/S0140-6736(05)71326-XSearch in Google Scholar
Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149: 601-8.LaaksonenDENiskanenLPunnonenKNyyssonenKTuomainenTPSalonenRet alSex hormones inflammation and the metabolic syndrome: a population-based studyEur J Endocrinol2003149601810.1530/eje.0.1490601Search in Google Scholar
Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003; 44: 322-8.NordCBjoroTEllingsenDMykletunADahlOKleppOet alGonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancerEur Urol200344322810.1016/S0302-2838(03)00263-XSearch in Google Scholar
Martinou M, Gaya A. Cardiac complications after radical radiotherapy. Semin Oncol 2013; 40: 178-85.MartinouMGayaACardiac complications after radical radiotherapySemin Oncol2013401788510.1053/j.seminoncol.2013.01.00723540743Search in Google Scholar
Vasiliadis I, Kolovou G, Mikhailidis DP. Cardiotoxicity and cancer therapy. Angiol 2014; 65: 369-71.VasiliadisIKolovouGMikhailidisDPCardiotoxicity and cancer therapyAngiol2014653697110.1177/000331971349829823921503Search in Google Scholar
Celik T, Yuksel C, Demirkol S, Iyisoy A, Ulutin C. Coronary artery disease associated with radiation therapy. Cent Eur J Med 2010; 5: 180-3.CelikTYukselCDemirkolSIyisoyAUlutinCCoronary artery disease associated with radiation therapyCent Eur J Med20105180310.2478/s11536-009-0068-8Search in Google Scholar
Wethal T, Kjekshus J, Roislien J, Ueland T, Andreassen AK, Wergeland R, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007; 1: 8-16.WethalTKjekshusJRoislienJUelandTAndreassenAKWergelandRet alTreatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancerJ Cancer Surviv2007181610.1007/s11764-007-0012-318648940Search in Google Scholar
Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow up. J Clin Oncol 2012; 30: 3752-63.HaugnesHSBoslGJBoerHGietemaJABrydoyMOldenburgJet alLong-term and late effects of germ cell testicular cancer treatment and implications for follow upJ Clin Oncol20123037526310.1200/JCO.2012.43.443123008318Search in Google Scholar
